{"id":60775,"date":"2025-08-22T23:37:23","date_gmt":"2025-08-22T23:37:23","guid":{"rendered":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/?p=60775"},"modified":"2025-08-22T23:37:23","modified_gmt":"2025-08-22T23:37:23","slug":"fatty-liver-modern-diagnosis-and-treatment-at-one-health-primary-care","status":"publish","type":"post","link":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/fatty-liver-modern-diagnosis-and-treatment-at-one-health-primary-care\/","title":{"rendered":"Fatty Liver: Modern Diagnosis and Treatment at One Health Primary Care"},"content":{"rendered":"<p>Fatty liver disease, a condition where excess fat accumulates in the liver, is a growing health concern worldwide. While a small amount of fat is normal, too much can lead to inflammation, scarring, and serious liver damage. The good news is that advancements in medical science have introduced new, non-invasive diagnostic methods and a groundbreaking treatment, offering hope for patients.<\/p>\n<p>At <strong>One Health Primary Care<\/strong>, we believe in a proactive approach to liver health. We use the latest diagnostic tools to provide accurate and timely care.<\/p>\n<p><strong>Understanding Fatty Liver Disease<\/strong><\/p>\n<p>Fatty liver disease is now often referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). A more severe form, which includes inflammation and liver cell damage, is known as metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH (non-alcoholic steatohepatitis). If left untreated, MASH can lead to liver cirrhosis (advanced scarring), liver failure, and even liver cancer.<\/p>\n<p><strong>Modern Diagnostic Methods: Beyond the Biopsy<\/strong><\/p>\n<p>Historically, a liver biopsy was the only definitive way to diagnose and stage fatty liver disease. While still a valuable tool, modern technology has provided non-invasive alternatives that are less painful and more convenient for patients.<\/p>\n<p>One of the most significant advancements is the use of transient elastography, a technology used in machines like the FibroScan and the FibroTouch by ILIVTouch. This method works by:<\/p>\n<ul>\n<li><strong>Measuring Liver Stiffness:<\/strong> The device sends a low-frequency shear wave into the liver. The speed at which this wave travels is measured to determine the stiffness of the liver tissue. A stiffer liver indicates the presence of fibrosis (scarring), which is a key indicator of disease progression.<\/li>\n<li><strong>Assessing Liver Fat:<\/strong> The machine also uses ultrasound to measure the Controlled Attenuation Parameter (CAP) or Ultrasound Attenuation Parameter (UAP). This measurement quantifies the amount of fat in the liver, providing a numerical score that helps doctors grade the severity of the fatty liver condition.<\/li>\n<\/ul>\n<p>The ILIVTouch FibroTouch machine, and similar devices, have made it possible for us to screen and monitor at-risk patients without resorting to a biopsy, allowing for earlier detection and intervention.<\/p>\n<p><strong>Groundbreaking Treatment: The First FDA-Approved Therapy<\/strong><\/p>\n<p>For years, the primary recommendation for fatty liver disease was lifestyle modification, specifically, diet and exercise. While these remain crucial, a new era of pharmaceutical treatment has begun with the recent approval of the first-ever medication for MASH.<\/p>\n<p>Madrigal Pharmaceuticals developed <strong>Rezdiffra\u2122 (resmetirom)<\/strong>, a drug that received accelerated FDA approval for the treatment of adults with noncirrhotic MASH who have moderate to advanced liver fibrosis. The drug works as a partial activator of a thyroid hormone receptor, specifically targeting the liver to reduce the accumulation of fat. Clinical trials have shown that Rezdiffra can improve liver fibrosis and resolve MASH in a significant number of patients.<\/p>\n<p>This approval is a historic milestone, offering a new treatment option for patients who previously had no medication to directly address their liver damage. It provides a targeted therapy that, in conjunction with diet and exercise, can help improve liver health before the disease progresses to more severe stages.<\/p>\n<p><strong>The Path Forward<\/strong><\/p>\n<p>The combination of non-invasive diagnostic tools and targeted pharmaceutical treatments represents a major leap forward in the fight against fatty liver disease. Patients at risk, including those with obesity, high blood pressure, and type 2 diabetes, can now be more easily screened and, if needed, receive a therapy that directly targets the underlying disease. As research continues, the future for patients with fatty liver disease looks more promising than ever.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fatty liver disease, a condition where excess fat accumulates in the liver, is a growing health concern worldwide. While a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60767,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[23],"tags":[],"class_list":["post-60775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-senior-care"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/posts\/60775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/comments?post=60775"}],"version-history":[{"count":1,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/posts\/60775\/revisions"}],"predecessor-version":[{"id":60776,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/posts\/60775\/revisions\/60776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/media\/60767"}],"wp:attachment":[{"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/media?parent=60775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/categories?post=60775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testv81.demowebsitelinks.com\/One-Health-Primary\/wp-json\/wp\/v2\/tags?post=60775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}